Roche Reports Sales Growth in Third Quarter
The pharmaceutical and diagnostics giant saw group sales rise as demand for innovative medicines increased globally.
Updated on Oct. 22, 2026 in Healthcare
Live Poll
Do you trust that pharmaceutical companies prioritize patient health outcomes over corporate sales growth?
Roche announced that its third-quarter sales grew by 7% at constant exchange rates. For the first nine months of 2026, the company recorded total group sales of 46.5 billion Swiss francs.
Why it matters
High demand for treatments targeting severe diseases served as a primary driver for the company's financial performance. This growth occurred despite healthcare pricing reforms impacting operations in China.
Group sales reached 46.5 billion Swiss francs for the first nine months of 2026. This reflects a 6% increase in sales at constant exchange rates compared to the prior period.
The players
Roche
Headquartered in Basel, Switzerland, this multinational healthcare company operates divisions focused on both pharmaceuticals and diagnostics.
US FDA
This federal regulatory agency oversees the approval and review process for medical devices and drugs within the United States.
The details
The firm’s Pharmaceuticals Division led with a 7% increase, while the Diagnostics Division saw 4% growth. Recent regulatory progress included US FDA clearance for the Elecsys pTau217 blood test and Priority Review status for fenebrutinib and giredestrant.
Timeline
January 2026 through September 2026 marks the period covered by the financial report.
Q3 2026 saw a 7% increase in sales at constant exchange rates.
October 22, 2026, is the date Roche published the sales report.
Market Landscape
Roche's performance reflects the ongoing struggle of global healthcare firms to balance innovation with China's healthcare pricing reforms. By leveraging core lab solutions, the company demonstrates a competitive strategy to maintain margins amidst regional regulatory headwinds.
Patients may gain faster access to new therapies following recent FDA regulatory clearances and priority reviews for potential treatments. Investors should monitor how the company meets its goal of bringing 20 new medicines to market by 2030.
The takeaway
Roche remains focused on long-term expansion through a robust pipeline of new medicine development. The company anticipates continued growth in the mid-single-digit range for total sales throughout the remainder of 2026.
Further reading
Find more industry updates on our Healthcare page.
Live Poll
Do you trust that pharmaceutical companies prioritize patient health outcomes over corporate sales growth?
